Citius Pharmaceuticals (NASDAQ:CTXR) Shares Up 13.7%

Citius Pharmaceuticals, Inc. (NASDAQ:CTXRGet Free Report)’s share price shot up 13.7% on Monday . The company traded as high as $0.62 and last traded at $0.60. 2,654,748 shares changed hands during trading, an increase of 104% from the average session volume of 1,301,384 shares. The stock had previously closed at $0.53.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating and set a $4.00 price objective on shares of Citius Pharmaceuticals in a report on Friday, May 31st.

Get Our Latest Research Report on Citius Pharmaceuticals

Citius Pharmaceuticals Stock Performance

The stock has a market capitalization of $134.74 million, a PE ratio of -3.11 and a beta of 1.68. The stock’s 50 day moving average is $0.64 and its two-hundred day moving average is $0.72.

Citius Pharmaceuticals (NASDAQ:CTXRGet Free Report) last released its earnings results on Tuesday, May 14th. The company reported ($0.05) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.01. Equities research analysts expect that Citius Pharmaceuticals, Inc. will post -0.21 EPS for the current fiscal year.

Institutional Trading of Citius Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in CTXR. Vanguard Group Inc. grew its stake in shares of Citius Pharmaceuticals by 1.5% in the first quarter. Vanguard Group Inc. now owns 7,005,119 shares of the company’s stock worth $6,286,000 after acquiring an additional 104,889 shares in the last quarter. BNP Paribas Financial Markets lifted its position in shares of Citius Pharmaceuticals by 88.5% during the 1st quarter. BNP Paribas Financial Markets now owns 69,615 shares of the company’s stock worth $62,000 after purchasing an additional 32,686 shares during the last quarter. Finally, Wealth Advisory Solutions LLC purchased a new stake in shares of Citius Pharmaceuticals during the 1st quarter worth $135,000. Institutional investors and hedge funds own 16.88% of the company’s stock.

Citius Pharmaceuticals Company Profile

(Get Free Report)

Citius Pharmaceuticals, Inc, a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome.

Further Reading

Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with's FREE daily email newsletter.